Semaglutide obesity treatment works by mimicking GLP-1 hormones to reduce appetite and slow gastric emptying, producing 15-20% weight loss in clinical

Semaglutide type 1 diabetes use remains off-label with limited evidence. We cover glycemic risks, trial data, and what current protocols actually

Semaglutide delivers 15–20% weight loss without surgery, while bariatric procedures achieve 25–35% reduction with permanent anatomical changes and higher

Semaglutide type 2 diabetes treatment lowers A1C by 1.5–2% through GLP-1 receptor activation, improving insulin sensitivity and slowing gastric emptying

Semaglutide improves insulin resistance by reducing hepatic glucose output up to 35% and increasing peripheral glucose uptake — reversing metabolic

Semaglutide reduces LDL cholesterol by 3–7% and triglycerides by 10–15% through weight loss, improved insulin sensitivity, and enhanced hepatic lipid

Semaglutide reduces prediabetes progression by 73% in clinical trials, preventing type 2 diabetes while improving weight and insulin sensitivity in

Semaglutide reduces cardiovascular events by 20% in high-risk patients but carries specific cardiac contraindications you must know before starting

Semaglutide reduces sleep apnea severity by 50–60% through weight loss and airway pressure reduction, with effects visible within 12–20 weeks of treatment.